Solara Active Pharma Sciences — Peer Comparison

How the peer fair value is calculated and which companies were used as benchmarks.

Peer selection

Peers are selected from the same Branded generics & specialty pharma industry. 8 companies were matched as valid comparables.

Same-industry peers share similar business models, cost structures, and growth prospects — making them the most appropriate benchmarks for valuation multiples.

Peer comparison table

Branded generics & specialty pharma · 8 peers · sector medians shown

Better than medianWorse than median

Company	Mkt Cap	P/E	P/B	EV/EBITDA	ROE	Net Margin	Rev CAGR 3y
Solara Active Pharma Sciences SOLARA · you	₹2,100 Cr	29.9×	2.6×	11.9×	-0.6%	-0.5%	-1.8%
Sector median	—	45.5×	4.5×	20.4×	10.3%	11.4%	15.7%
Marksans Pharma Limited MARKSANS	₹13,495 Cr	32.9×	4.5×	20.7×	13.8%	14.2%	16.8%
CORONA Remedies Limited CORONA	₹12,727 Cr	64.4×	16.0×	46.6×	24.8%	13.2%	16.6%
Sanofi Consumer Healthcare India Limited SANOFICONR	₹10,285 Cr	45.5×	28.4×	31.4×	62.5%	27.3%	—
Strides Pharma Science Limited STAR	₹8,923 Cr	36.7×	2.5×	—	6.9%	0.1%	—
Medplus Health Services Limited MEDPLUS	₹7,968 Cr	45.5×	5.1×	12.1×	11.1%	3.2%	14.8%
Aarti Pharmalabs Limited AARTIPHARM	₹7,617 Cr	35.9×	3.0×	20.4×	8.2%	9.6%	-2.2%
Shilpa Medicare Limited SHILPAMED	₹7,366 Cr	47.5×	4.5×	18.2×	9.4%	15.8%	13.6%
Viyash Scientific Limited VIYASH	₹6,642 Cr	67.6×	4.1×	11.0×	6.1%	5.2%	34.0%

Peer comparison verdict

Solara trades at a discount to sector peers on P/E (29.9× vs median 45.5×). This may signal undervaluation — or reflect lower expected growth or higher perceived risk versus the peer group.

Why median? Why these weights?

Median over mean: The sector median is used instead of the average because valuation multiples have extreme outliers — one high-growth company at 200× P/E would dramatically skew a mean. The median gives the middle value in the peer set, which better represents typical pricing.

Sector-specific weights: The weight given to each method reflects what matters most in this sector. For banks, P/B dominates because their value is tied to book assets. For IT companies, P/E carries the most weight because earnings quality matters more than asset base. For capital-intensive businesses, EV/EBITDA accounts for varying debt levels across peers and removes financing structure bias.

Limitations of peer comparison

Peer comparison assumes comparable companies are truly comparable — which is never perfectly true. Sector classifications can be imperfect: a conglomerate classified as "IT" may also have significant manufacturing revenue. Small peer counts (below 5) reduce confidence, as a single outlier can skew the sector median. When the entire sector is broadly expensive, peer comparison will show even an expensive stock as "fairly valued" relative to its peers.

The peer fair value shown is an algorithmic estimate based on publicly available financial data. It is not investment advice or a recommendation to buy, sell, or hold any security. Please consult a SEBI-registered investment adviser before making any investment decision.